Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells

Shinn Liang Lai, Jaulang Hwang, Reury Perng Perng, Jacqueline Whang-Peng

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


To obtain cisplatin (CDDP)-resistant cells possessing the clinically induced resistance phenotype, H-460 nonsmall cell lung cancer cells (NSCLC) were pulse treated with 20, 60, 80 μM CDDP for 1 h every week, respectively. Twelve months later, three CDDP-resistant cell lines (H-460/CDDP20, H460/CDDP60, H-460/CDDP80) were obtained that exhibit different levels of CDDP resistance (6- to 22 fold), and the possible mechanisms of resistance were studied. These resistant cells were cross-resistant to carboplatin and melphalan, but not to adriamycin or 5-fluorouracil. CDDP resistance in these cell lines appeared to be stable even after 6 months of growth in cisplatin-free medium. There was no evidence of drug accumulation differences between parental and resistant cells. Although both intracellular glutathione (GSH) content and glutathione S-transferase (GST) activity increased 1.5- to 2.5-fold in the resistant cells, only a minimal reversal of drug resistance was observed after buthionine sulfoximine (BSO) treatment, which depleted intracellular GSH levels. An enhancement of DNA repair activity was found in the resistant cell lines and played the major role in the cisplatin resistance phenotype. Using H-460/CDDP80 cells as a model, addition of a nontoxic concentration of pentoxifylline (PTX) significantly enhanced CDDPinduced cytotoxicity in a synergistic manner. Furthermore, more prominent reversal of CDDP resistance could be achieved when the resistant cells were pretreated with BSO, followed by PTX and CDDP combined treatment. This provides a rationale for combination therapy in refractory lung cancer using CDDP and two resistance modulators.

Original languageEnglish
Pages (from-to)31-38
Number of pages8
JournalOncology Research
Issue number1
Publication statusPublished - 1995
Externally publishedYes


  • acquired drug resistance
  • buthionine sulfoximine
  • cisplatin
  • nonsmall cell lung cancer
  • pentoxifylline
  • resistance modulators

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells'. Together they form a unique fingerprint.

Cite this